DTIL News

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting ® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting ® 2025

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30 th Annual International Congress of the World Muscle Society

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6 th International Coalition to Eliminate HBV Cure Symposium